Your selections:
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
- Smith, Amanda M., Dun, Matthew D., Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan
Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants
- Mashkani, Baratali, Griffith, Renate, Ashman, Leonie
FMS-like tyrosine kinase 3 (FLT3) inhibitors: molecular docking and experimental studies
- Mashkani, Baratali, Tanipour, Mohammad Hossein, Saadatmandzadeh, Mohammad, Ashman, Leonie K., Griffith, Renate
Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia
MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1
- Kim, Kyu-Tae, Carroll, Adam P., Mashkani, Baratali, Cairns, Murray J., Small, Donald, Scott, Rodney J.
Molecular and phosphoproteomic characterisation of FLT3 inhibitor resistance in acute myeloid leukaemia
- Staudt Barreto, Dilana Elisabeth
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
- Staudt, Dilana, Murray, Heather C., McLachlan, Tabitha, Alvaro, Frank, Enjeti, Anoop K., Verrills, Nicole M., Dun, Matthew D.
Targeting PP2A activation as a novel therapeutic strategy for receptor tyrosine kinase driven leukaemia
Are you sure you would like to clear your session, including search history and login status?